Grégory Driessens

发表

Highly Successful Therapeutic Vaccinations Combining Dendritic Cells and Tumor Cells Secreting Granulocyte Macrophage Colony-stimulating Factor

C. Bruyns, T. Velu, G. Driessens, 2004, Cancer Research.

β-Catenin Inhibits T Cell Activation by Selective Interference with Linker for Activation of T Cells–Phospholipase C-γ1 Phosphorylation

F. Gounari, Yan Zheng, T. Gajewski, 2011, The Journal of Immunology.

SOX2 controls tumour initiation and cancer stem-cell functions in squamous-cell carcinoma

S. Rorive, I. Salmon, Sylvain Brohée, 2014, Nature.

Defining the mode of tumour growth by clonal analysis

C. Blanpain, B. Simons, Amélie Caauwe, 2012, Nature.

Therapeutic efficacy of antitumor dendritic cell vaccinations correlates with persistent Th1 responses, high intratumor CD8+ T cell recruitment and low relative regulatory T cell infiltration

P. Stordeur, C. Bruyns, T. Velu, 2008, Cancer Immunology, Immunotherapy.

A vascular niche and a VEGF–Nrp1 loop regulate the initiation and stemness of skin tumours

P. Carmeliet, J. Haigh, S. Loges, 2011, Nature.

Inhibition of Tryptophan-Dioxygenase Activity Increases the Antitumor Efficacy of Immune Checkpoint Inhibitors

B. J. Van den Eynde, L. Pilotte, V. Stroobant, 2019, Cancer Immunology Research.

Inhibition of tryptophan-dioxygenase activity increases the anti-tumor efficacy 1 of immune checkpoint inhibitors 2

S. Crosignani, J. Preillon, K. Frederix, 2019 .

β-catenin does not regulate memory T cell phenotype

Yan Zheng, T. Gajewski, G. Driessens, 2010, Nature Medicine.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Charles J. Vaske, Joe Y. Chang, Scott R. Presnell, 2016, Journal for ImmunoTherapy of Cancer.

Glucose deprivation inhibits multiple key gene expression events and effector functions in CD8+ T cells

T. Gajewski, C. Cham, G. Driessens, 2008, European journal of immunology.

Costimulatory and coinhibitory receptors in anti‐tumor immunity

T. Gajewski, G. Driessens, Gregory Driessens, 2009, Immunological reviews.

Restoration of T-cell Effector Function, Depletion of Tregs, and Direct Killing of Tumor Cells: The Multiple Mechanisms of Action of a-TIGIT Antagonist Antibodies

N. Wald, M. Cragg, M. Bagot, 2020, Molecular Cancer Therapeutics.

Synergy Between Dendritic Cells and GM–CSF-secreting Tumor Cells for the Treatment of a Murine Renal Cell Carcinoma

A. Zlotta, C. Bruyns, T. Velu, 2009, Journal of immunotherapy.

TIGIT inhibition and lenalidomide synergistically promote antimyeloma immune responses after stem cell transplantation in mice

S. Furlan, D. Sester, G. Hill, 2022, The Journal of clinical investigation.

TIG-007: Study of EOS884448/GSK4428859A Alone, and in Combination with Iberdomide with or without Dexamethasone, in Participants with Relapsed or Refractory Multiple Myeloma

P. Moreau, G. Hill, Y. McGrath, 2021, Blood.

Transcriptional regulator early growth response gene 2 (Egr2) is required for T cell anergy in vitro and in vivo

Yan Zheng, T. Gajewski, F. Locke, 2012, The Journal of experimental medicine.

Development of a successful antitumor therapeutic model combining in vivo dendritic cell vaccination with tumor irradiation and intratumoral GM-CSF delivery

L. Tenenbaum, V. Préat, C. Bruyns, 2011, Cancer Immunology, Immunotherapy.

A designer ligand specific for Kv1.3 channels from a scorpion neurotoxin-based library

M. Biancalana, A. Koide, S. Koide, 2009, Proceedings of the National Academy of Sciences.

Abstract CT118: Preliminary data from Phase I first-in-human study of EOS884448, a novel potent anti-TIGIT antibody, monotherapy shows favorable tolerability profile and early signsof clinical activity in immune-resistant advanced cancers

J. Machiels, S. Rottey, C. Jungels, 2021, Clinical Trials.